Our data showed that the elevation of FGFR2 and CEBPB in HB-tumor and in a subgroup of CC patients are restricted to bile duct only, and CEBPB and FGFR2 was markedly over-expressed in 6.5% (2 of the 31) and 22.6% (7 of the 31) CC patients, respectively. The gene discussed is CEBPB; the disease is cholangiocarcinoma.